Pixyl.Neuro.BV

Pixyl

Pixyl.Neuro.BV is a volumetry tool measuring brain atrophy. It integrates into the routine workflow to quantify the volume of different tissues and structures in the brain, as well as any changes from the previous visit if there is one (longitudinal analysis). It also compares patient values to a normative population. The software outputs a quantitative report on tissue and structure volume, and changes relative to the prior visit. It also provides graphs to visualize the evolution of certain volumes with respect to normative values.
Product specifications Information source: Vendor
Last updated: Feb. 19, 2023
General
Product name Pixyl.Neuro.BV
Company Pixyl
Subspeciality Neuro
Modality MR
Disease targeted Neurodegenerative diseases, dementia, Alzheimer’s disease, Multiple Sclerosis, Parkinson’s disease
Key-features Brain volume quantification, brain segmentation, comparison with normative values, longitudinal analysis
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps)
Data characteristics
Population patients with known or suspected neurodegenerative disease
Input MR sequence, 3D T1-weighted image
Input format DICOM
Output structured quantitative report, table of quantified values, comparison with normative values, graphs of volume evolution with respect to normative values, brain MRI representative screenshots, longitudinal analysis
Output format PDF report, DICOM report
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes
Certification
CE
Certified, Class IIa , MDD
FDA
 No or not yet
Market presence
On market since 10-2019
Distribution channels Incepto, GE, Siemens, Osimis
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Subscription
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers